Effect of Erythropoietin on Preterm Brain Injury

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

EPO has been safely used for prevent preterm anemia and recent studies have shown the neuroprotective effect. Our hypothesis is that EPO could prevent preterm brain injury. The aims of this study include: to investigate the safety and efficacy of EPO by using 500u/kg higher than the dose of anemia treatment (250u/kg); to evaluate the effect of EPO on neurodevelopment in preterm infants; to detect biological indicators and explore the neuroprotective mechanism of EPO.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhengzhou Children's Hospital, China
• Collaborator: Zhengzhou University
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Preterm infants admitted to the NICU with gestational age <32 weeks

• birth weight <1500g and less than 72hours of age

Exclusion Criteria:

• 1. Infants with genetic metabolic diseases

2. Congenital abnormalities

3. Pneumothorax

4. Grade III-IV intracranial hemorrhage